Compare Stocks: CVKD, BGM, ACTU, and ATNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$1.15 -1.7%	$1.71	$1.03 ▼ $9.22	$27.52M	0.67	170,629 shs	65,833 shs
ATNM Actinium Pharmaceuticals	$0.84 +0.7%	$1.01	$0.81 ▼ $1.81	$26.45M	-0.02	141,334 shs	10,344 shs
BGM BGM Group	$0.27 +0.8%	$0.33	$0.25 ▼ $11.80	$26.64M	1.78	301,789 shs	29,308 shs
CVKD Cadrenal Therapeutics	$2.01 -3.9%	$3.33	$1.86 ▼ $14.64	$6.97M	1.73	62,063 shs	8,574 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	+8.33%	-7.14%	-22.98%	-60.20%	-83.91%
ATNM Actinium Pharmaceuticals	+0.01%	-6.06%	-14.59%	-24.59%	-46.69%
BGM BGM Group	-5.13%	-6.50%	-26.06%	-7.24%	-96.99%
CVKD Cadrenal Therapeutics	+5.08%	+2.96%	-37.43%	-68.67%	-80.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$1.15 -1.7%	$1.71	$1.03 ▼ $9.22	$27.52M	0.67	170,629 shs	65,833 shs
ATNM Actinium Pharmaceuticals	$0.84 +0.7%	$1.01	$0.81 ▼ $1.81	$26.45M	-0.02	141,334 shs	10,344 shs
BGM BGM Group	$0.27 +0.8%	$0.33	$0.25 ▼ $11.80	$26.64M	1.78	301,789 shs	29,308 shs
CVKD Cadrenal Therapeutics	$2.01 -3.9%	$3.33	$1.86 ▼ $14.64	$6.97M	1.73	62,063 shs	8,574 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	+8.33%	-7.14%	-22.98%	-60.20%	-83.91%
ATNM Actinium Pharmaceuticals	+0.01%	-6.06%	-14.59%	-24.59%	-46.69%
BGM BGM Group	-5.13%	-6.50%	-26.06%	-7.24%	-96.99%
CVKD Cadrenal Therapeutics	+5.08%	+2.96%	-37.43%	-68.67%	-80.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	2.50	Moderate Buy	$13.67	1,088.41% Upside
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	493.12% Upside
BGM BGM Group	1.00	Sell	N/A	N/A
CVKD Cadrenal Therapeutics	2.00	Hold	$13.00	547.09% Upside

Current Analyst Ratings Breakdown

Latest CVKD, BGM, ACTU, and ATNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	ACTU Actuate Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
7/17/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	ACTU Actuate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/10/2026	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/18/2026	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.34 per share	N/A
ATNM Actinium Pharmaceuticals	$90K	293.88	N/A	N/A	$1.31 per share	0.64
BGM BGM Group	$37.92M	0.70	N/A	N/A	$4.03 per share	0.07
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$22.23M	-$0.97	N/A	N/A	N/A	N/A	-430.93%	-180.86%	N/A
ATNM Actinium Pharmaceuticals	-$48.82M	-$0.75	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
BGM BGM Group	-$19.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	-$13.24M	-$5.63	N/A	N/A	N/A	N/A	-411.03%	-275.61%	8/10/2026 (Estimated)

Latest CVKD, BGM, ACTU, and ATNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	CVKD Cadrenal Therapeutics	-$1.42	N/A	N/A	N/A	N/A	N/A
7/21/2026	Q4 2025	BGM BGM Group	N/A	-$0.0750	N/A	-$0.0750	N/A	$11.80 million
5/14/2026	Q1 2026	ACTU Actuate Therapeutics	-$0.23	-$0.24	-$0.01	-$0.24	N/A	N/A
5/7/2026	Q4 2025	CVKD Cadrenal Therapeutics	-$1.51	-$1.04	+$0.47	-$1.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	1.80	1.80
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
BGM BGM Group	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	2.68	2.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
ATNM Actinium Pharmaceuticals	27.50%
BGM BGM Group	N/A
CVKD Cadrenal Therapeutics	7.92%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	57.98%
ATNM Actinium Pharmaceuticals	0.60%
BGM BGM Group	58.66%
CVKD Cadrenal Therapeutics	26.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	23.93 million	10.05 million	N/A
ATNM Actinium Pharmaceuticals	30	31.38 million	29.32 million	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
CVKD Cadrenal Therapeutics	4	3.42 million	2.53 million	Not Optionable

CVKD, BGM, ACTU, and ATNM Headlines

Recent News About These Companies

Q2 EPS Estimate for Cadrenal Therapeutics Raised by Analyst

July 25, 2026 | americanbankingnews.com

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

July 21, 2026 | globenewswire.com

Cadrenal Therapeutics Announces Chief Medical Officer Transition

July 17, 2026 | tipranks.com

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 ...

July 14, 2026 | markets.businessinsider.com

Cadrenal Therapeutics Presents Positive Phase 2 CAD-1005 Data in Late-Breaking ISTH Oral Presentation for Heparin-Induced Thrombocytopenia

July 13, 2026 | quiverquant.comQ

Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

July 13, 2026 | globenewswire.com

Cadrenal Therapeutics Announces Chief Medical Officer Resignation

July 10, 2026 | tipranks.com

Insider Selling: Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells 7,400 Shares of Stock

July 3, 2026 | insidertrades.com

Cadrenal Therapeutics Secures Private Placement to Extend Runway

July 1, 2026 | tipranks.com

Cadrenal Therapeutics Announces $3 Million Private Placement with Potential Additional $5.8 Million from Warrants

June 30, 2026 | quiverquant.comQ

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 30, 2026 | globenewswire.com

Cadrenal Names Interim CFO, Realigns Board Structure

June 29, 2026 | tipranks.com

Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells $27,538.45 in Stock

June 27, 2026 | insidertrades.com

Cadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 9,167 Shares

June 25, 2026 | insidertrades.com

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

June 24, 2026 | globenewswire.com

Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells 3,613 Shares

June 19, 2026 | insidertrades.com

Cadrenal Pursues Rare Pediatric Designation for Tecarfarin

June 18, 2026 | tipranks.com

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

June 18, 2026 | globenewswire.com

Insider Selling: Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells 3,666 Shares of Stock

June 16, 2026 | insidertrades.com

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming ...

June 15, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CVKD, BGM, ACTU, and ATNM Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$1.15 -0.02 (-1.71%)

As of 01:26 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Actinium Pharmaceuticals NYSE:ATNM

$0.84 +0.01 (+0.72%)

As of 01:18 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

BGM Group NASDAQ:BGM

$0.27 +0.00 (+0.81%)

As of 01:30 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Cadrenal Therapeutics NASDAQ:CVKD

$2.01 -0.08 (-3.88%)

As of 01:30 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVKD, BGM, ACTU, and ATNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVKD, BGM, ACTU, and ATNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVKD, BGM, ACTU, and ATNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CVKD, BGM, ACTU, and ATNM Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

Actinium Pharmaceuticals NYSE:ATNM

BGM Group NASDAQ:BGM

Cadrenal Therapeutics NASDAQ:CVKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVKD, BGM, ACTU, and ATNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVKD, BGM, ACTU, and ATNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVKD, BGM, ACTU, and ATNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CVKD, BGM, ACTU, and ATNM Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

Actinium Pharmaceuticals NYSE:ATNM

BGM Group NASDAQ:BGM

Cadrenal Therapeutics NASDAQ:CVKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools